CD36：乳腺癌中对HER2抑制剂耐药的关键介质。
CD36: a key mediator of resistance to HER2 inhibitors in breast cancer.
作者信息
Feng William W, Bang Scott, Kurokawa Manabu
机构信息
Department of Biological Sciences, Kent State University, Kent, OH, USA.
Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
出版信息
Mol Cell Oncol. 2020 Jan 23;7(2):1715766. doi: 10.1080/23723556.2020.1715766. eCollection 2020.
Abstract
Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy.
摘要
获得性抗HER2治疗耐药是乳腺癌治疗中的一项重大临床挑战。我们最近发现，在获得对HER2抑制的耐药过程中，脂肪酸转运蛋白CD36会发生上调，在代谢重塑和抗HER2治疗耐药中起关键作用。
相似文献
1
CD36: a key mediator of resistance to HER2 inhibitors in breast cancer.CD36：乳腺癌中对HER2抑制剂耐药的关键介质。
Mol Cell Oncol. 2020 Jan 23;7(2):1715766. doi: 10.1080/23723556.2020.1715766. eCollection 2020.
3
Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.双脂肪酸合酶和HER2信号通路阻断对耐抗HER2药物的乳腺癌模型显示出显著的抗肿瘤活性。
PLoS One. 2015 Jun 24;10(6):e0131241. doi: 10.1371/journal.pone.0131241. eCollection 2015.
4
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.针对甲羟戊酸途径克服乳腺癌获得性抗 HER2 治疗耐药性。
Mol Cancer Res. 2019 Nov;17(11):2318-2330. doi: 10.1158/1541-7786.MCR-19-0756. Epub 2019 Aug 16.
5
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.Yes1信号传导介导乳腺癌对曲妥珠单抗/拉帕替尼的耐药性。
PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017.
6
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.PI3Kα/δ显性抑制剂BAY 80 - 6946在对HER2靶向治疗药物曲妥珠单抗和拉帕替尼产生获得性耐药的HER2阳性乳腺癌模型中的临床前评估。
Breast Cancer Res Treat. 2015 Jan;149(2):373-83. doi: 10.1007/s10549-014-3239-5. Epub 2014 Dec 21.
7
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.评估曲妥珠单抗和拉帕替尼联合化疗作为HER2阳性乳腺癌新辅助治疗的双抗HER2治疗的随机CHER-LOB研究的前瞻性生物标志物分析
Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5.
8
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.达可替尼（PF-00299804），一种不可逆的泛 HER 抑制剂，可抑制曲妥珠单抗和拉帕替尼耐药的 HER2 扩增乳腺癌细胞系的增殖。
Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.
9
10
Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer.脂肪酸合酶赋予雌激素受体阳性/人表皮生长因子受体2阳性乳腺癌对他莫昔芬的耐药性。
Cancers (Basel). 2021 Mar 6;13(5):1132. doi: 10.3390/cancers13051132.
引用本文的文献
1
Lipid metabolism involved in progression and drug resistance of breast cancer.脂质代谢与乳腺癌的进展和耐药性有关。
Genes Dis. 2024 Jul 15;12(4):101376. doi: 10.1016/j.gendis.2024.101376. eCollection 2025 Jul.
2
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.脂质代谢重编程：乳腺癌进展和肿瘤微环境中被忽视的英雄。
Mol Cancer. 2025 Mar 3;24(1):61. doi: 10.1186/s12943-025-02258-1.
3
Role of CD36 in cancer progression, stemness, and targeting.CD36在癌症进展、干性及靶向治疗中的作用
Front Cell Dev Biol. 2022 Dec 8;10:1079076. doi: 10.3389/fcell.2022.1079076. eCollection 2022.
4
An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer.乳腺癌中对人表皮生长因子受体2（Her2）靶向治疗的耐药性概述。
Cancer Drug Resist. 2022 Jun 1;5(2):472-486. doi: 10.20517/cdr.2022.09. eCollection 2022.
5
Targeting lipid metabolism in the treatment of ovarian cancer.靶向脂质代谢治疗卵巢癌。
Oncotarget. 2022 May 25;13:768-783. doi: 10.18632/oncotarget.28241. eCollection 2022.
6
Prognostic and immunological role of CD36: A pan-cancer analysis.CD36的预后和免疫作用：一项泛癌分析。
J Cancer. 2021 Jun 11;12(16):4762-4773. doi: 10.7150/jca.50502. eCollection 2021.
7
In Vivo Optical Metabolic Imaging of Long-Chain Fatty Acid Uptake in Orthotopic Models of Triple-Negative Breast Cancer.三阴性乳腺癌原位模型中长链脂肪酸摄取的体内光学代谢成像
Cancers (Basel). 2021 Jan 5;13(1):148. doi: 10.3390/cancers13010148.
本文引用的文献
1
CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies.CD36 介导的乳腺癌细胞代谢重编程促进对 HER2 靶向治疗的耐药性。
Cell Rep. 2019 Dec 10;29(11):3405-3420.e5. doi: 10.1016/j.celrep.2019.11.008.
2
A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.MDM2 和 HUWE1 E3 泛素连接酶的底物网络独立于 p53 控制细胞凋亡。
Sci Signal. 2013 May 7;6(274):ra32. doi: 10.1126/scisignal.2003741.
3
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.脂肪酸合酶磷酸化：HER2 过表达乳腺癌细胞的一个新的治疗靶点。
Breast Cancer Res. 2010;12(6):R96. doi: 10.1186/bcr2777. Epub 2010 Nov 16.
4
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.BCR-ABL 酪氨酸激酶抑制剂治疗费城染色体阳性慢性髓性白血病：综述。
Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016.
5
CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior.CD36，一种参与免疫、代谢、血管生成和行为的清道夫受体。
Sci Signal. 2009 May 26;2(72):re3. doi: 10.1126/scisignal.272re3.
6
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.克服对酪氨酸激酶抑制剂的耐药性：从接受表皮生长因子受体拮抗剂治疗的癌细胞中吸取的经验教训。
Cell Cycle. 2009 Jan 1;8(1):18-22. doi: 10.4161/cc.8.1.7324. Epub 2009 Jan 30.
7
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis.脂肪酸合酶与癌症发病机制中的脂肪生成表型
Nat Rev Cancer. 2007 Oct;7(10):763-77. doi: 10.1038/nrc2222.
8
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.MET扩增通过激活ERBB3信号通路导致肺癌对吉非替尼耐药。
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.
9
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.疾病机制：了解人类乳腺癌对HER2靶向治疗的耐药性
Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509.
10
Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis.人表皮生长因子受体2（HER2）的转录组分析揭示了其与脂肪酸合成之间的分子联系。
Cancer Res. 2003 Jan 1;63(1):132-9.
Zotero 插件